Literature DB >> 25125726

The immune system in hypertension.

David G Harrison1.   

Abstract

Hypertension is generally attributed to perturbations of the vasculature, the kidney, and the central nervous system. During the past several years, it has become apparent that cells of the innate and adaptive immune system also contribute to this disease. Macrophages and T cells accumulate in the kidneys and vasculature of humans and experimental animals with hypertension, and likely contribute to end-organ damage. We have shown that mice lacking lymphocytes, such as recombinase-activating gene-deficient (RAG-1(-/-)) mice, have blunted hypertension in response to angiotensin II, increased salt levels, and norepinephrine. Adoptive transfer of T cells restores the blood pressure response to these stimuli. Others have shown that mice with severe combined immunodeficiency have blunted hypertension in response to angiotensin II. Deletion of the RAG gene in Dahl salt-sensitive rats reduces the hypertensive response to salt feeding. The central nervous system seems to orchestrate immune cell activation. We produced lesions of the anteroventral third ventricle and showed that these block T cell activation in response to angiotensin II. Likewise, we showed that genetic manipulation of reactive oxygen species in the subfornical organ modulates both hypertension and T cell activation. Current evidence indicates that production of cytokines including tumor necrosis factor alpha, interleukin 17, and interleukin 6 contribute to hypertension, likely by promoting vasoconstriction, production of reactive oxygen species, and sodium reabsorption in the kidney. We propose a working hypothesis linking the sympathetic nervous system, immune cells, the production of cytokines, and ultimately vascular and renal dysfunction, leading to augmentation of hypertension.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25125726      PMCID: PMC4112677     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  41 in total

Review 1.  Immune mechanisms in experimental and essential hypertension.

Authors:  D J Dzielak
Journal:  Am J Physiol       Date:  1991-03

2.  Angiotensin II hypertension is attenuated in interleukin-6 knockout mice.

Authors:  Dexter L Lee; Lashon C Sturgis; Hicham Labazi; James B Osborne; Cassandra Fleming; Jennifer S Pollock; Marlina Manhiani; John D Imig; Michael W Brands
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-11       Impact factor: 4.733

3.  Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system.

Authors:  Chanran K Ganta; Ning Lu; Bryan G Helwig; Frank Blecha; Roman R Ganta; Ling Zheng; Christopher R Ross; Timothy I Musch; Richard J Fels; Michael J Kenney
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-05-20       Impact factor: 4.733

4.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.

Authors:  G Wallukat; V Homuth; T Fischer; C Lindschau; B Horstkamp; A Jüpner; E Baur; E Nissen; K Vetter; D Neichel; J W Dudenhausen; H Haller; F C Luft
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice.

Authors:  Cissy C Zhou; Yujin Zhang; Roxanna A Irani; Hong Zhang; Tiejuan Mi; Edwina J Popek; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Nat Med       Date:  2008-07-27       Impact factor: 53.440

6.  IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy.

Authors:  Laura I Schrader; Dale A Kinzenbaw; Andrew W Johnson; Frank M Faraci; Sean P Didion
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-25       Impact factor: 8.311

Review 7.  Th17 cells in human disease.

Authors:  Laura A Tesmer; Steven K Lundy; Sujata Sarkar; David A Fox
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Regulatory T cells ameliorate angiotensin II-induced cardiac damage.

Authors:  Heda Kvakan; Markus Kleinewietfeld; Fatimunnisa Qadri; Joon-Keun Park; Robert Fischer; Ines Schwarz; Hans-Peter Rahn; Ralph Plehm; Maren Wellner; Saban Elitok; Petra Gratze; Ralf Dechend; Friedrich C Luft; Dominik N Muller
Journal:  Circulation       Date:  2009-05-26       Impact factor: 29.690

9.  Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.

Authors:  Raymond E Eid; Deepak A Rao; Jing Zhou; Sheng-fu L Lo; Hooman Ranjbaran; Amy Gallo; Seth I Sokol; Steven Pfau; Jordan S Pober; George Tellides
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

10.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more
  47 in total

Review 1.  Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertension.

Authors:  Sudhakar Veeranki; Siva K Gandhapudi; Suresh C Tyagi
Journal:  Can J Physiol Pharmacol       Date:  2016-04-28       Impact factor: 2.273

2.  Gut dysbiosis is linked to hypertension.

Authors:  Tao Yang; Monica M Santisteban; Vermali Rodriguez; Eric Li; Niousha Ahmari; Jessica Marulanda Carvajal; Mojgan Zadeh; Minghao Gong; Yanfei Qi; Jasenka Zubcevic; Bikash Sahay; Carl J Pepine; Mohan K Raizada; Mansour Mohamadzadeh
Journal:  Hypertension       Date:  2015-04-13       Impact factor: 10.190

3.  Evidence for a Causal Role of the SH2B3-β2M Axis in Blood Pressure Regulation.

Authors:  Joshua A Keefe; Shih-Jen Hwang; Tianxiao Huan; Michael Mendelson; Chen Yao; Paul Courchesne; Mohamed A Saleh; Meena S Madhur; Daniel Levy
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

4.  Interleukin-6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats.

Authors:  Shireen Hashmat; Nathan Rudemiller; Hayley Lund; Justine M Abais-Battad; Scott Van Why; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-08

Review 5.  Carotid baroreflex activation therapy for resistant hypertension.

Authors:  Ronald G Victor
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

6.  Toll-Like Receptors, Hypertension, and an Antimalarial Drug.

Authors:  Madhu V Singh
Journal:  Am J Hypertens       Date:  2016-10-04       Impact factor: 2.689

7.  Selective IgE deficiency and cardiovascular diseases.

Authors:  Eli Magen; Joseph Mishal; Daniel Vardy
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

Review 8.  Sex-specific immune modulation of primary hypertension.

Authors:  Kathryn Sandberg; Hong Ji; Meredith Hay
Journal:  Cell Immunol       Date:  2014-12-08       Impact factor: 4.868

9.  Hypertension, Anxiety, and Blood-Brain Barrier Permeability Are Increased in Postpartum Severe Preeclampsia/Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome Rats.

Authors:  Kedra Wallace; Cynthia Bean; Teylor Bowles; Shauna-Kay Spencer; Wisdom Randle; Patrick B Kyle; James Shaffery
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

10.  Role of immune factors in angiotensin II-induced hypertension and renal damage in Dahl salt-sensitive rats.

Authors:  Brittany Wade; Galina Petrova; David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-08       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.